Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-26-088126
Filing Date
2026-07-29
Accepted
2026-07-29 16:03:51
Documents
8
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 28491
2 EXHIBIT 99.2 tm2621582d1_ex99-2.htm EX-99.2 505903
3 GRAPHIC tm2621582d1_ex99-2header.jpg GRAPHIC 2867
4 GRAPHIC tm2621582d1_ex99-2img01.jpg GRAPHIC 22651
5 GRAPHIC tm2621582d1_ex99-2img02.jpg GRAPHIC 20702
6 GRAPHIC tm2621582d1_ex99-2img03.jpg GRAPHIC 17106
7 GRAPHIC tm2621582d1_ex99-2img04.jpg GRAPHIC 29113
8 GRAPHIC tm2621582d1_ex99-2img05.jpg GRAPHIC 29544
  Complete submission text file 0001104659-26-088126.txt   705164
Mailing Address ZERNIKEDREEF 9 LEIDEN Netherlands
Business Address ZERNIKEDREEF 9 LEIDEN Netherlands 31 88 166 7000
ProQR Therapeutics N.V. (Subject) CIK: 0001612940 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88671 | Film No.: 261217323
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address LICHTENAUERLAAN 30 ROTTERDAM P7 3062ME
Business Address LICHTENAUERLAAN 30 ROTTERDAM P7 3062ME 0031102411555
VAN HERK INVESTMENTS B.V. (Filed by) CIK: 0001633120 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A